TY - JOUR
T1 - Cancer-associated thrombosis in patients with implanted ports
T2 - A prospective multicenter French cohort study (ONCOCIP)
AU - ONCOCIP Investigators
AU - Decousus, Hervé
AU - Bourmaud, Aurélie
AU - Fournel, Pierre
AU - Bertoletti, Laurent
AU - Labruyère, Carine
AU - Presles, Emilie
AU - Merah, Adel
AU - Laporte, Silvy
AU - Stefani, Laetitia
AU - Del Piano, Francesco
AU - Jacquin, Jean Philippe
AU - Meyer, Guy
AU - Chauvin, Franck
AU - Berthelot, P.
AU - Mismetti, P.
AU - Tardy, B.
AU - Minozzi, C.
AU - Scotte, F.
AU - Ayala, S.
AU - Bach, Y.
AU - Bada, H.
AU - Chacornac, O.
AU - Durif, J.
AU - Pierre, M.
AU - Collard, O.
AU - Guillot, A.
AU - Mery, B.
AU - Roche, L. Saban
AU - Vassal, C.
AU - Baconnier, M.
AU - Decroisette, C.
AU - Heudel, P. E.
AU - Maillard, E.
AU - Mermet, L.
AU - Bedjaoui, A.
AU - Delouane, M.
AU - Laurent, T.
AU - Bacha, K. Mahour
AU - Romand, P.
AU - Bosset, M.
AU - El Demery, M.
AU - Lantheaume, S.
AU - Sensenbrenner, F.
AU - Barletta, H.
AU - Alliot, C.
AU - Arimont, J. M.
AU - Bouclier, J. B.
AU - Chatellain, P.
AU - Huet, F.
AU - Muron, T.
N1 - Publisher Copyright:
© 2018 by The American Society of Hematology.
PY - 2018/8/16
Y1 - 2018/8/16
N2 - The need to accurately identify cancer outpatients at high risk of thrombotic complications is still unmet. In a prospective, multicenter cohort study (ONCOlogie et Chambres ImPlantables [ONCOCIP]), consecutive adult patients with a solid tumor and implanted port underwent 12-month follow-up. Our primary objective was to identify risk factors for (1) catheter-related thrombosis, defined as ipsilateral symptomatic upper-limb deep-vein thrombosis with or without pulmonary embolism, and (2) venous thromboembolism other than catheter-related, defined as any symptomatic superficial- or deep-vein thrombosis (other than catheter-related) or pulmonary embolism, and incidental pulmonary embolism. All events were objectively confirmed and centrally adjudicated. Rate assessments integrated competing risk of death. Overall, 3032 patientswere included (median age: 63 years; women: 58%). The most frequent cancer locations were breast (33.7%), lung (18.5%), and colorectal (15.6%), cancer being metastatic in 43.2% of patients. Most patients (97.1%) received chemotherapy. By 12 months, 48 (1.6%) patients had been lost to follow-up and 656 (24.6%) had died; 3.8% (n = 111) of patients had experienced catheter-related thrombosis, and 9.6% (n = 276) venous thromboembolism other than catheter-related. By multivariate analysis, use of cephalic vein for catheter insertion predicted catheter-related thrombosis, whereas ongoing antiplatelet therapy was protective; risk factors for venous thromboembolism other than catheter-related were advanced age, previous venous thromboembolism, cancer site, and low hemoglobin level or increased leukocyte count before chemotherapy. In conclusion, this large prospective cohort study showed a high rate of venous thromboembolism in patients with a solid tumor and implanted port. Risk factors for catheter-related thrombosis differed from those for venous thromboembolism not catheterrelated.
AB - The need to accurately identify cancer outpatients at high risk of thrombotic complications is still unmet. In a prospective, multicenter cohort study (ONCOlogie et Chambres ImPlantables [ONCOCIP]), consecutive adult patients with a solid tumor and implanted port underwent 12-month follow-up. Our primary objective was to identify risk factors for (1) catheter-related thrombosis, defined as ipsilateral symptomatic upper-limb deep-vein thrombosis with or without pulmonary embolism, and (2) venous thromboembolism other than catheter-related, defined as any symptomatic superficial- or deep-vein thrombosis (other than catheter-related) or pulmonary embolism, and incidental pulmonary embolism. All events were objectively confirmed and centrally adjudicated. Rate assessments integrated competing risk of death. Overall, 3032 patientswere included (median age: 63 years; women: 58%). The most frequent cancer locations were breast (33.7%), lung (18.5%), and colorectal (15.6%), cancer being metastatic in 43.2% of patients. Most patients (97.1%) received chemotherapy. By 12 months, 48 (1.6%) patients had been lost to follow-up and 656 (24.6%) had died; 3.8% (n = 111) of patients had experienced catheter-related thrombosis, and 9.6% (n = 276) venous thromboembolism other than catheter-related. By multivariate analysis, use of cephalic vein for catheter insertion predicted catheter-related thrombosis, whereas ongoing antiplatelet therapy was protective; risk factors for venous thromboembolism other than catheter-related were advanced age, previous venous thromboembolism, cancer site, and low hemoglobin level or increased leukocyte count before chemotherapy. In conclusion, this large prospective cohort study showed a high rate of venous thromboembolism in patients with a solid tumor and implanted port. Risk factors for catheter-related thrombosis differed from those for venous thromboembolism not catheterrelated.
UR - http://www.scopus.com/inward/record.url?scp=85053621803&partnerID=8YFLogxK
U2 - 10.1182/blood-2018-03-837153
DO - 10.1182/blood-2018-03-837153
M3 - Article
C2 - 29980524
AN - SCOPUS:85053621803
SN - 0006-4971
VL - 132
SP - 707
EP - 716
JO - Blood
JF - Blood
IS - 7
ER -